Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
73°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Autolus Therapeutics plc - American Depositary Shares
(NQ:
AUTL
)
1.540
+0.010 (+0.65%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 23, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Autolus Therapeutics plc - American Depositary Shares
< Previous
1
2
3
4
5
6
7
Next >
12 Health Care Stocks Moving In Friday's Intraday Session
December 09, 2022
Via
Benzinga
Why Autolus Therapeutics Stock Is Crashing Today
December 09, 2022
The biopharmaceutical company announced the pricing of a secondary stock offering.
Via
The Motley Fool
US Stocks Edge Lower; Producer Prices Increase Higher Than Expected
December 09, 2022
U.S. stocks traded slightly lower this morning following the release of PPI data
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
December 09, 2022
Via
Benzinga
Autolus Therapeutics' Leukemia Trial Meets Primary Goal Of Remission Rate, Shares Fall After $150M Capital Raise
December 09, 2022
Via
Benzinga
Why Autolus Therapeutics Shares Are Trading Lower By Around 26%; Here Are 28 Stocks Moving Premarket
December 09, 2022
Gainers Baudax Bio, Inc. (NASDAQ: BXRX) shares rose 48.2% to $6.03 in pre-market trading after jumping over 20% on Thursday. Baudax Bio initiated Phase II clinical trial evaluating BX1000 in patients...
Via
Benzinga
Autolus Therapeutics: Q3 Earnings Insights
November 03, 2022
Autolus Therapeutics (NASDAQ:AUTL) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
December 09, 2022
The trading week is almost complete but we've still got the biggest pre-market stock movers to go over for Friday morning!
Via
InvestorPlace
Autolus Announces Pricing of Public Offering
December 08, 2022
From
Autolus Therapeutics plc
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
December 08, 2022
Via
Benzinga
Moderna In-Licenses Autolus' Technology For mRNA-Based Cancer Therapeutics
October 12, 2022
Via
Benzinga
Recap: Autolus Therapeutics Q2 Earnings
August 04, 2022
Autolus Therapeutics (NASDAQ:AUTL) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Autolus Announces Proposed Public Offering in the United States
December 08, 2022
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics to Receive $70 Million in Milestone Payments from Blackstone Life Sciences
December 08, 2022
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics announces pivotal Phase 2 FELIX clinical trial has met primary endpoint at interim analysis
December 08, 2022
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics announces handover of first clean rooms of new Stevenage, UK, manufacturing facility
November 30, 2022
From
Autolus Therapeutics plc
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
November 15, 2022
Via
Benzinga
Autolus Therapeutics to Present Three Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2022
November 03, 2022
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics Reports Third Quarter 2022 Financial Results and Operational Progress
November 03, 2022
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics to Report Third Quarter 2022 Financial Results on November 3, 2022
October 21, 2022
From
Autolus Therapeutics plc
Via
GlobeNewswire
Moderna exercises option to license proprietary targeting technology from Autolus
October 12, 2022
From
Autolus Therapeutics plc
Via
GlobeNewswire
11 Health Care Stocks Moving In Wednesday's Pre-Market Session
October 05, 2022
Gainers Bionano Genomics (NASDAQ:BNGO) stock increased by 9.8% to $2.24. The company's market cap stands at $649.9 million.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
October 05, 2022
It's time for another overview of the biggest pre-market stock movers for Wednesday as we cover the news behind share movement this morning!
Via
InvestorPlace
R&D Efforts to Improve Optimal Treatments for Advanced Pancreatic Ductal Adenocarcinoma (PDAC) Progressing
October 05, 2022
Palm Beach, FL – October 5, 2022 – FinancialNewsMedia.com News Commentary – Advanced pancreatic ductal adenocarcinoma (PDAC) remains a significant cause of mortality accounting for up to 4% of all...
Via
FinancialNewsMedia
Topics
Death
Exposures
Death
12 Health Care Stocks Moving In Tuesday's Intraday Session
October 04, 2022
Gainers
Via
Benzinga
Why AeroClean Technologies Shares Are Trading Higher By Around 38%, Here Are 58 Stocks Moving In Tuesday's Mid-Day Session
October 04, 2022
Gainers Bit Brother Limited (NASDAQ: BTB) rose 229% to $0.3688 after declining around 14% on Monday.
Via
Benzinga
Autolus Therapeutics Stock Jumps After Bristol Myers Pact For Safety Switch System
October 04, 2022
Via
Benzinga
Autolus Therapeutics Announces Collaboration with Bristol Myers Squibb for Use of Autolus’ Proprietary Safety Switch System
October 04, 2022
From
Autolus Therapeutics plc
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
September 21, 2022
Gainers Scopus BioPharma (NASDAQ:SCPS) stock moved upwards by 10.9% to $0.3 during Wednesday's pre-market session. The market value of their outstanding shares is at $6.3 million.
Via
Benzinga
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
May 05, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.